A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas

Blood

Volumn 96, Issue 9, 2000, Pages 2934-2942

  Press, O W ^a   Eary, J F ^a   Gooley, T ^a   Gopal, A K ^a   Liu, S ^a   Rajendran, J G ^a   Maloney, D G ^a   Petersdorf, S ^a   Bush, S A ^a   Durack, L D ^a   Martin, P J ^a   Fisher, D R ^a   Wood, B ^a   Borrow, J W ^a   Porter, B ^a   Smith, J P ^a   Matthews, D C ^a   Appelbaum, F R ^a   Bernstein, I D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; MONOCLONAL ANTIBODY; TOSITUMOMAB IODINE I 131; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SCINTILLATION CAMERA; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0034329326     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.2934.h8002934_2934_2942     Document Type: Article

References (40)

1. Current approaches to the management of non-Hodgkin's lymphoma
2. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
3. Treatment approaches to the low-grade lymphomas
4. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
5. Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia
6. Radiolabeled antibody therapy of B cell lymphomas with autologous bone marrow support
7. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
8. Follow-up of relapsed B cell lymphoma patients treated with I-131-labeled anti-CD20 (anti-B1 antibody) and autologous stem cell rescue
9. Imaging and treatment of B-cell lymphoma
10. Preliminary validation of the opposing view method for quantitative gamma camera imaging
11. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies
12. Regimen-related toxicity in patients undergoing bone marrow transplantation
13. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting
14. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population
15. Identification of monoclonal B-cell populations by rapid cycle polymerase chain reaction: A practical screening method for the detection of immunoglobulin gene rearrangements
16. All advanced stage non Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
17. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas
18. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
19. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
20. A predictive model for aggressive non Hodgkin's lymphoma: The International Non Hodgkin's Lymphoma Prognostic Factors Project
21. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
22. Determinants of the antitumor effect of radiolabeled monoclonal antibodies
23. A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: Effects of tumor burden and antigen expression
24. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody
25. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B cell lymphoma
26. 131-LYM-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma
27. 131I-LYM-1 antibody
28. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies
29. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody
30. Conventional and hematopoietic stem cell supported radioimmunotherapy with humanized Y-90-LL2 (Y-90hLL2) anti-CD22 monoclonal antibody in NHL patients who failed high dose therapy
31. + B-cell non-Hodgkin's lymphoma
32. Prospective randomized controlled study of zevalin (Idec-Y2B8) radioimmunotherapy compared to rituximab immunotherapy for B-cell NHL: Report of interim results
33. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma
34. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma
35. Myelodysplasc syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma
36. Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy
37. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies
38. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma
39. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors